Epizyme, Inc. (NASDAQ:EPZM) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02, Bloomberg Earnings reports.
In related news, Director David M. Mott bought 200,000 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was bought at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the purchase, the director now owns 6,000 shares in the company, valued at approximately $91,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the sale, the insider now owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,000 shares of company stock valued at $733,950. 25.20% of the stock is currently owned by corporate insiders.
A number of research firms have weighed in on EPZM. BidaskClub lowered shares of Epizyme from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Jefferies Group LLC began coverage on shares of Epizyme in a research report on Wednesday, September 20th. They set a “buy” rating and a $23.00 target price for the company. Royal Bank Of Canada set a $20.00 target price on shares of Epizyme and gave the stock a “buy” rating in a research report on Saturday, August 5th. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Tuesday, July 18th. Finally, HC Wainwright reissued a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Epizyme has a consensus rating of “Buy” and an average price target of $23.78.
COPYRIGHT VIOLATION WARNING: “Epizyme, Inc. (EPZM) Announces Earnings Results” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://sportsperspectives.com/2017/11/01/epizyme-inc-epzm-announces-earnings-results.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.